Leukotriene

The information on this site is intended for health care professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Prescribing Information Patient Information Return to singulair.com

Leukotrienes and allergic rhinitis

Leukotrienes play an important role in contributing to the signs and symptoms of allergic rhinitis. Learn more about what your patients may experience following exposure to an allergen trigger.

Learn about the role of leukotrienes

Early and late phase responses
Mast cells and eosinophils
Causing symptoms of allergic rhinitis

Early- and late-phase responses

Find out more about the role
of leukotrienes.

More information

SINGULAIR® (montelukast sodium) has not been assessed in intranasal challenge studies. The clinical relevance of intranasal challenge studies is unknown.
Leukotrienes and Allergic Rhinitis

View clinical studies

Symptoms and leukotrienes
See the results of a clinical study that examined symptom severity based on leukotriene concentrations and pollen count.

See Results

Increased eosinophils
See the results of a clinical study that examined the relationship between the increase of eosinophils with pollen count and symptom severity.

See Results

Pathophysiology animation

Pathophysiology Animation

Watch an animated video illustrating the important role leukotrienes play in causing the signs and symptoms of allergic rhinitis.

Watch video.

Download animation.
[PowerPoint (PPT) format, 5.2 MB]

SINGULAIR is indicated for relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and children aged 2 years and older and perennial allergic rhinitis in adults and children aged 6 months and older).

SELECTED SAFETY INFORMATION

  • Neuropsychiatric events have been reported in patients taking SINGULAIR. These events included agitation, aggressive behavior or hostility, anxiousness, depression, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some postmarketing reports appear consistent with a drug-induced effect. Patients should be advised to report any neuropsychiatric events.
  • In clinical trials in patients with allergic rhinitis, adverse events varied by age. The most commonly reported adverse events, occurring at a frequency of >1% and at an incidence greater than placebo, regardless of causality assessment, were sinusitis, upper respiratory infection, sinus headache, cough, epistaxis, headache, otitis media, pharyngitis, and increased ALT.
  • SINGULAIR is contraindicated in patients with hypersensitivity to any component of this product.

Before prescribing SINGULAIR, please read the Prescribing Information.

20951837(3)-02/10-SNG

For general information and other services for physicians

Merck Services Merck OnCall

SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.